The incidence of complete thyroxine-binding globulin (TBG) deficiency (TBG-CD) was determined for a Japanese population from a comprehensive health examination, in which a T3 resin uptake test of the upper 5% (78 subjects from among 1,589 men) was the screening line for TBG-CD. Further analysis of the known mutation in TBG-CDgene of the Japanese population (reported as TBG-CDJwith codon 352 deletion) was performed on 72 subjects, and three were found to have TBG-CDJ,two of whomwere siblings. Only those three subjects had a serum TBG concentration of less than 5 mg/l. The six subjects for whomthe DNAanalysis was not performed, did not have a serum TBGlevel of less than 5 mg/Z. From these findings, the gene frequency ofTBG-CDJ was calculated to be 0.13%. The incidence of TBG-CDJin the total Japanese population is suggested to be 0.09%. (Internal Medicine 35: 266-269, 1996) 
Introduction
Thyroxine-binding globulin (TBG), the major transport protein for thyroid hormones in humanserum, is synthesized in the liver. It consists of 395 amino acids and 4 aspargine-linked oligosaccharide chains (1), andbinds 70% of the thyroxine (T4) and triiodothyronine (T3) in human serum (2). The TBG gene is located on the long arm of the X chromosome (3), which is composed of five exons (4, 5) . Complete TBG deficiency (TBG-CD) was first reported by Nicoloff et al in 1964 (6) . Yamamori et al reported a single nucleotide deletion at codon 352 (TBG-CDJ)in six unrelated Japanese families with TBG-CD(7). A frameshift by a nucleotide deletion at codon 352 ofTBG-CDJresults in a 22 amino acid truncation and a further 22 amino acid divergence at the C terminus. This mutation causes loss of biological activity. The mechanismhas been evaluated in an expression experiment (8). TBG-CDJ is synthesized as a truncated molecule and retained within the rough endoplasmic reticulum, resulting in complete absence of secretion. The incidence ofTBG-CDhas been investigated in neonatal screening programs for hypothyroidism (9-1 3), in which TT4 has been used. TBG-CDwas found in the group of low TT4.
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However, in these studies, molecular genetic analysis for TBG-CD was not carried out. The genotype of TBG-CDwas not investigated. We previously reported a single family with hereditary TBG-CDfrom data of an abnormally elevated T3 resin uptake test that had been included as a screening for thyroid function ( 14). Subsequently, we performed TBGscreening for the adult Japanese population by performing the T3 resin uptake test in comprehensive health examinations, which was the aim of the present study. Further, wecarried out molecular genetic analysis related to TBG-CDand determined the genotype of TBG-CD.
Materials and Methods

Comprehensivehealth examination program
From April 1990 to March 1991, 1,589 men underwent comprehensive health examinations at Sakuragaoka Hospitel. As part ofa screening program, we included the T3 resin uptake test in these examinations. Amongthe subjects showing a high T3 resin uptake, the upper 5% (78 males) were selected for measurementof serum TBGconcentration and for molecular genetic analysis by polymerase chain reaction (PCR) ( 1 5) of the TBG gene.
Thyroid function tests Serum concentrations offree T4 and TSHwere measured, as well as titers of anti-thyroglobulin antibody and anti-thyroid microsomal antibody for 3 cases whose serum TBGconcentrations were less than 5.0 mg/7. The serum TBGconcentrations were determined by RIAgnost TBGkit (Hoechst Japan, Tokyo). Serum free T4 concentrations were determined by analogue method RIA (Amerlex-M FT4, Amersham International, Tokyo). Serum TSHconcentrations were determined by immunoradiometric assay (Spac TSH, Daiichi Isotope Co., Tokyo). The titers of anti-thyroglobulin antibody were determined by gelatin-particle agglutination test (Serodia-ATG, Fujirebio Inc., Tokyo). The titers of anti-thyroid microsomal antibody were determined by gelatin-particle agglutination test (Serodia-AMC, Fujirebio Inc.). In three cases where the serum TBGconcentrations were less than 5.0 mg// in the RIA, the TBGconcentration was further measured by a highly sensitive chemiluminescent enzyme immunoassay (CLEIA) (Luminomaster TBG, Sankyo Co., Tokyo).
DNAanalysis
The DNAanalysis was performed by a method which was different from the method reported previously (14). Genomic DNAwas extracted from peripheral white blood cells as described elsewhere (4). Oligonucleotide primers (F and R) were designed to amplify the part ofexon 4 including codon 352 (7). With oligonucleotide primers F and R, a DNAfragment of 95 or 94 base pairs was amplified by PCR. The PCRproducts were digested with EcoRI, electrophoresed in 8% polyaerylamide gels, and visualized with UVlight after staining with ethidium bromide.
Results
Serum concentration of TBGand DNAanalysis
As shown in Table 1 , serum TBGconcentrations were determined for 63 males. The remaining 15 subjects could not be examined due to sample loss. Serum TBGconcentrations of less than 5.0 mg// were obtained forthree subjects and, as shown in Fig. 1 cases. The serum TBGconcentrations of60 subjects were more than 5.0 mg//. Amongthem, DNAanalysis was performed in 54 cases. Their PCRproducts were not digested with EcoRI. DNA analysis was not performed in the remaining 6 cases due to loss of peripheral white blood cell samples. In the remaining 15 subjects whoseserumTBGconcentrations were not determined, the PCR products were not digested with EcoRI.
Thyroid function in subjects with TBGdeficiency As shown in Table 2 , of the three subjects with serum TBG concentrations of less than 5.0 mg//, two were brothers (No. 2 and No. 3). T3 resin uptake tests of the three subjects gave results of more than 50%. Serum TSH, FT4, anti-thyroid microsomal antibody and anti-thyroglobulin antibody titers were determined for two subjects (No. 1 and No. 2). Their serum TSHand FT4levels were within normal ranges, as were their anti-thyroid microsomal antibody and anti-thyroglobulin antibody titers. The thyroid function of the third subject was not examined. By CLEIA, the serum TBGconcentration of one male (No. 2) was less than 0.5 mg//.
Discussion
Two methods have been reported for identifying the deletion of the first base c at codon 352 of the TBGgene. One method, used here, employs primers designed to form the restriction site of EcoRI in the PCR product from the mutant gene (7). The other method uses allele-specific primers (14, 16). The presence of the same mutation with TBG-CDJ was first checked by PCRfor the three cases with TBGconcentrations of less than 5.0 mg//. Whenthe same mutation with TBG-CDJ could not be confirmed, all of the nucleotide sequences of the TBGgene had to be determined. But the three subjects were TBG-CDJ, which is reported to be acommon cause ofTBG-CD in Japanese (16). The 60 males whose serum TBGconcentrations were greater than 5.0 mg//, could not have been TBG-CD. The PCRproducts of the 15 cases with unknownserum TBG concentrations were not digested with EcoRI, indicating that these cases were not TBG-CDJ. In such cases, there maybe unknown types of TBG-CDgene other than TBG-CDJ.However, the possibility of a subject having a serum TBGconcentration of less than 5.0 mg//, is less than one { 15x(3/63) } based on the data that the serum TBGconcentration was less than 5.0 mg// in 3 cases among 63 patients.
The molecular biological bases of hereditary TBG-CDhave been studied in French Canadian (17), English (18), and Japanese (7) subjects, with the mutations reported being a single nucleotide substitution at codon 227 (17) and a single nucleotide deletion at codon 165 (18) or at codon 352 (7), respectively. All of the TBG-CDin Japanese for whomgenetic analysis was done, including our 3 TBG-CDcases, harbored the single nucleotide deletion at codon 352. Furthermore, this has been detected only in Japanese, suggesting that the mutation appeared in the ancestors of the Japanese after the divergence of the humanraces and spread amongJapanese descendants by the founder effect. The linkage disequilibrium by haplotype analysis should clarify the founder effect, which has been investigated in other diseases including myotonic dystrophy (19, 20) and cystic fibrosis (21). As two of the three TBG-CDJ males were siblings, the calculated gene frequency was 2 in 1,588, or 0.13%. Wecould not inquire the number of siblings in the denominator. But, even if there were 100 pairs of siblings, the re-calculated gene frequency should be 0.13% (2: 1,488). As our comprehensive health examination is a workshop examination, the rate of siblings may be even smaller. Consequently, the calculated gene frequency ofTBG-CDJ is expected to be virtually the true frequency.
In evaluating the incidence of complete TBGdeficiency, it should be recognized that TBG-CDis inherited in the X-linked codominant mode, and thus females carrying TBG-CDalleles are usually recognized as having TBGpartial deficiency due to the heterozygousity. Homozygous females can be recognized as having TBGcomplete deficiency, but such a probability is almost negligible, being (0.0013)2 = 0.00000169 from the data of gene frequency. The ratio of both sexes in the Japanese in the 1990's, was almost 96.5: 100 (male:female) (22). Accordingly, we corrected the number of females based on the ratio among the Japanese in this period, i.e., the number of males multiplied by 100/96.5 was 1,647. This 1,647 multiplied by 0.00000169 was 0.0028, which is extremely small. By adding 1,647 to the denominator, the incidence of TBG-CDJwas calculated to be 0.09%. This incidence is almost equal to that found in neonatal screening of the Japanese (1:1,200 to 1:1,900) (9, 10), and is higher than in Caucasians (1:5,000 to 1:13,000) (1 1-13).
TBG-CDs of previous reports ofneonatal screening in Japan were not studied further regarding genotypes. Thus some other types of mutant TBG-CDgenes may exist in such subjects. However, in the present study, all subjects with TBGdeficiency had the TBG-CDJ gene. This suggests that TBG-CDwith a mutation of the TBG gene other than TBG-CDJ must be extremely rare. Thus, the incidence of TBG-CDseems to be almost identical with that ofTBG-CDJin the Japanese popula- 
